Research group Prof. Dr. Klaus Langer

Director of the Institute

Pharmacist

Room: C.110.159

Phone: +49 (0)251 - 83-39860
Fax: +49 (0)251 - 83-39308
E-Mail: k.langer(AT)uni-muenster(DOT)de

Research

Prof. Langer: Research and teaching

Research Foci

Drug Targeting mittels Nanotechnologie
Zielspezifische Tumortherapie
Formulierung von Arzneistoffen

Academic Education

2005: Habilitation und Venia legendi im Fach "Pharmazeutische Technologie", Goethe-Universität Frankfurt
01.1992 – 10.1996: Promotionsarbeit im Fach "Pharmazeutische Technologie", Johann Wolfgang Goethe-Universität Frankfurt

Positions

since 03.2009: Universitätsprofessor für Pharmazeutische Technologie, WWU Münster
11.1996 – 02.2009: Wissenschaftlicher Mitarbeiter am Institut für Pharmazeutische Technologie, Goethe-Universität Frankfurt
2000: Gastprofessur für Pharmazeutische Technologie, Karl-Franzens-Universität Graz
11.1990 – 10.1991: Pharmazeutisches Praktikum in einer Apotheke und bei der STADA Arzneimittel AG

Honors

2022: Goldener Spatel in the category "Gute Lehre" – Studierende der Pharmazie und des Masters Arzneimittelwissenschaften der Universität Münster
2016: PHOENIX Pharmazie Wissenschaftspreis – PHOENIX group
2016: Teaching Prize – University of Münster
2008: Preis des Fachbereichs Biochemie, Chemie und Pharmazie für exzellente Lehre – Goethe-Universität, Frankfurt
2003: Adolf Messer Prize – Adolf Messer Foundation

Projects

W2-Stiftungsprofessur mit Tenure-Track auf eine W3-Professur (Stiftungslehrstuhl) "Pharmazeutische Technologie" (2023 – 2033)
Individual Granted Project: Rottendorf Stiftung
Regenerativer Einsatz nanopartikulärer Substanzen zur Auflösung von Kalzifikationen der Retina – REpAIR (2025 – 2028)
Individual Granted Project: Bundesministerium für Forschung, Technologie und Raumfahrt | Project Number: 03VP13100
PharMSchool (2019 – 2027)
Individual Granted Project: Universitätsgesellschaft Münster e.V., Deutsche Pharmazeutische Gesellschaft e.V., Rottendorf Stiftung
Self Immolative Drug Delivery Systems based on Polycarbonate Copolymers (2022 – 2025)
Individual Granted Project: DFG - Sachbeihilfe/Einzelförderung | Project Number: LA 1165/5-3
Entwicklung einer Arzneiform zur TG-1-Enzymsubstitution der lamallären Ichthyose (2021 – 2024)
Individual Granted Project: United for Fighting Ichthyosis - Amici per la Pelle
Stabilisierung von nanopartikulären pharmazeutischen Wirkstoffen durch humanes Serumalbumin (HSA) (2020 – 2023)
Individual Granted Project: INVITE GmbH
Self Immolative Drug Delivery Systems based on Polycarbonate Copolymers (2018 – 2022)
Individual Granted Project: DFG - Sachbeihilfe/Einzelförderung | Project Number: LA 1165/5-1
Transglutaminase 1-Liposomen - Forschungsarbeiten auf dem Gebiet der lamellären Ichthyose (2020 – 2021)
Individual Granted Project: Leibniz-Forschungsinstitut für Molekulare Pharmakologie
Patientenrelevanz generischer Substitution am Beispiel von L-Dopa (2018 – 2021)
Individual Granted Project: Apothekerstiftung Westfalen-Lippe | Project Number: Wa/mie
EXC 1003 B1 - Formation and Properties of Epithelial and Endothelial Barriers (2012 – 2019)
Subproject in DFG-Joint Project Hosted at the University of Münster: DFG - Exzellenzcluster | Project Number: EXC1003/1
Auftragsanalytik (REM, DSC, ...) für den Bereich der Arzneimittelherstellung (2013 – 2018)
Individual Granted Project: Rottendorf Pharma GmbH
Verbundprojekt: Zielgesteuerte BioTransporter oral applizierter Photosensibilisatoren zur photodynamischen Therapie gastrointestinaler Carcinome (GITCare) - Teilvorhaben: Nanostrukturierte Trägersysteme und deren biologische Bewertung (2015 – 2018)
Participation in Federally Funded Joint Project: Bundesministerium für Forschung, Technologie und Raumfahrt | Project Number: 13N13423
Rezepturfit - Validierung von Rezepturprozessen (2016 – 2017)
Individual Granted Project: Apothekerstiftung Westfalen-Lippe
PharMSchool-Symposium (2017)
Scientific Event: Sonstige Mittelgeber
Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms – BioTraP for CCC (2011 – 2015)
Participation in Federally Funded Joint Project: Bundesministerium für Forschung, Technologie und Raumfahrt | Project Number: 13N11390
Development for nanoparticles for Parkinson disease (2013 – 2014)
Individual Granted Project: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
Stem cell generation and manipulation by nanoparticle mediated gene transfer for the safe clinical application of gene-modified cells – NanoGene (2011 – 2014)
Participation in Federally Funded Joint Project: Bundesministerium für Forschung, Technologie und Raumfahrt | Project Number: 13N1I539
ERA-NET Neuron NanoBrain – NanoBrain (2010 – 2013)
Individual Granted Project: Sonstige Mittelgeber
Schaltbare Nanopartikel als Wirkstoffträger (2010 – 2012)
Own Resources Project
Development of cell type specific drug carrier systems for cancer therapy – NanoCancer (2006 – 2010)
Own Resources Project
Nanoparticulate dosage forms for specific tumor therapy – NanoDrug (2004 – 2007)
Own Resources Project

Publications

Research Articles (Journals)

2023

Subeska, A, Voundi, M.E., Hanekamp, W., Mulac, D., Langer, K., and Lehr, M. 2023. “Synthesis, activity, metabolic stability and cell permeability of new cytosolic phospholipase A2α inhibitors with 1-indolyl-3-phenoxypropan-2-one structure.” Bioorganic and Medicinal Chemistry Letters 92: 129374–129374. doi: 10.1016/j.bmcl.2023.129374.
Hardebeck, S., Schreiber, S., Adick, A., Langer, K., and Jose, J. 2023. “A FRET-based assay for the identification of PCNA inhibitors.” International Journal of Molecular Sciences 24. doi: 10.3390/ijms241411858.
Adick, A., Hoheisel, W., Schneid, S., Mulac, D., Azhdari, S., and Langer, K. 2023. “Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension.” European journal of pharmaceutics and biopharmaceutics 193: 129–143. doi: 10.1016/j.ejpb.2023.10.022.
Weitzel, J., Wünsch, A., Erzkamp, S., Rose, O., and Langer, K. 2023. “Problems with the change in generics: Justified complaints or only imagination of the patients? Probleme beim Generikawechsel Berechtigte Klagen oder nur Einbildung der Patienten?” Deutsche Apotheker-Zeitung 163 (2).
Hester, S., Ferenz, K.B., Adick, A., Kakalias, C., Mulac, D., Azhdari, S., and Langer, K. 2023. “Triglyceride-filled albumin-based nanocapsules: A promising new system to avoid discarding poorly water-soluble drug candidates.” International Journal of Pharmaceutics 646. doi: 10.1016/j.ijpharm.2023.123454.
Feldmann, A., Nitschke, Y., Linss, F., Mulac, D., Stuecker, S., Bertrand, J., Buers, I., Langer, K., and Rutsch, F. 2023. “Improved reversion of calcifications in porcine aortic heart valves using elastin-targeted nanoparticles.” International Journal of Molecular Sciences 24 (22). doi: 10.3390/ijms242216471.
Subeska, A., Althaus, J., Hake, T., Hanekamp, W., Bettenworth, D., Mulac, D., Langer, K., and Lehr, M. 2023. “Synthesis and pharmacokinetic properties of novel cPLA2α inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure.” Bioorganic & Medicinal Chemistry 77: 117110–117110. doi: 10.1016/j.bmc.2022.117110.

2022

Hahn, M., Lindemann, V., Behrens, M., Mulac, D., Langer, K., Esselen, M., and Humpf, H.-U. 2022. “Permeability of dopamine D2 receptor agonist hordenine across the intestinal and blood-brain barrier in vitro.” PloS one 17 (6): e0269486–e0269486. doi: 10.1371/journal.pone.0269486.
Weitzel, J., Wünsch, A., Rose, O., and Langer, K. 2022. “Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.” International Journal of Pharmaceutics 629: 122401–122401. doi: 10.1016/j.ijpharm.2022.122401.
Barth, C., Spreen, H., Mulac, D., Keuter, L., Behrens, M., Humpf, H.-U., and Langer, K. 2022. “Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles.” Biomaterials and Biosystems 5: 100032. doi: 10.1016/j.bbiosy.2021.100032.
Barth, M., Rudolph, S., Kampschulze, J., Meyer zu Vilsendorf, I., Hanekamp, W., Mulac, D., Langer, K., and Lehr, M. 2022. “Hexafluoroisopropyl carbamates as selective MAGL and dual MAGL/FAAH inhibitors: Biochemical and physicochemical properties.” ChemMedChem 17: e2021007. doi: 10.1002/cmdc.202100757.
Weitzel, J., Langer, K., and Rose, O. 2022. “Effects of generic exchange of levodopa medication in patients with Parkinson disease.” Journal of Patient Safety 18 (7). doi: 10.1097/PTS.0000000000001015.
Rust, T., Jung, D., Langer, K., and Kuckling, D. 2022. “Stimuli-accelerated polymeric drug delivery systems.” Polymer International 72 (1). doi: 10.1002/pi.6474.
Spreen, H., Barth, C., Keuter, L., Mulac, D., Humpf, H.-U., and Langer, K. 2022. “Tuning the protein corona of PLGA nanoparticles: Characterization of trastuzumab adsorption behavior and its cellular interaction with breast cancer cell lines.” Journal of Drug Delivery Science and Technology 74. doi: 10.1016/j.jddst.2022.103543.

2021

Wünsch, A., Mulac, D., and Langer, K. 2021. “Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier.” International Journal of Pharmaceutics 593: 120146.
Rust, T., Jung, D., Hoppe, A., Schoppa, T., Langer, K., and Kuckling, D. 2021. “Backbone-degradable (co-)polymers for light-triggered drug delivery.” ACS Applied Polymer Materials 2021: 3831–3842.
Jung, D., Rust, T., Völlmecke, K., Schoppa, T., Langer, K., and Kuckling, D. 2021. “Backbone vs. side-chain: Two light-degradable polyurethanes based on 6-nitropiperonal.” Polymer Chemistry 12: 4565–4575. doi: 10.1039/d1py00442e.
Hester, S., Ferenz, K.B., Eitner, S., and Langer, K. 2021. “Development of a lyophilization process for long term storage of albumin based perfluorodecalin filled artificial oxygen carriers.” Pharmaceutics 13: 584.
Langer, K. 2021. “mRNA- und DNA-Impfstoffe – Nanotechnologie der Covid-19-Vakzinen.” Pharmazeutische Zeitung 166: 1024–1031.
Schoppa, T., Jung, D., Rust, T., Mulac, D., Kuckling, D., and Langer, K. 2021. “Light-responsive nanoparticles based on a novel nitropiperonal derived polyester as drug delivery systems for photosensitizers in PDT.” International Journal of Pharmaceutics 597: 120326..
Spreen, H., Behrens, M., Mulac, D., Humpf, H., and Langer, K. 2021. “Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles.” European journal of pharmaceutics and biopharmaceutics 163: 212–222.

2020

Langer, K. 2020. “Adjuvanzien im Europäischen Arzneibuch – Adjuvants in the European Pharmacopoeia.” Pharmakon 8: 351–356.
Wünsch, A., Mulac, D., and Langer, K. 2020. “Lipoprotein imitating nanoparticles: Lecithin coating binds ApoE and mediates non-lysosomal uptake leading to transcytosis over the blood-brain barrier.” International Journal of Pharmaceutics 589: 119821.
Mecate-Zambrano, A., Sukumar, S., Seebohm, G., Ciminski, K., Schreiber, A., Anhlan, D., Greune, L., Wixler, L., Grothe, S., Stein, N.C., Schmidt, M.A., Langer, K., Schwemmle, M., Shi, T., Ludwig, S., and Boergeling, Y. 2020. “Discrete spatio-temporal regulation of tyrosine phosphorylation directs influenza A virus M1 protein towards its function in virion assembly.” PLoS Pathogens 16: e1008775.
Sahnen, F., Kamps, J.P., and Langer, K. 2020. “Conversion of indomethacin nanosuspensions into solid dosage forms via fluid bed granulation and compaction.” European journal of pharmaceutics and biopharmaceutics 154: 89–97.
Weitzel, J., Langer, K., Erzkamp, S., and Rose, O. 2020. “Effects of generic exchange of solid oral dosage forms in neurological disorders: A systematic review.” International Journal of Clinical Pharmacy 42: 393–417.
Keuth, J., Nitschke, Y., Mulac, D., Riehemann, K., Rutsch, F., and Langer, K. 2020. “Reversion of arterial calcification by elastin-targeted DTPA-HSA nanoparticles.” European journal of pharmaceutics and biopharmaceutics 150: 108–119.

2019

Pieper, S., Onafuye, H., Mulac, D., Cinatl, J., Wass, M.N., Michaelis., M., and Langer, K. 2019. “Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity.” Beilstein Journal of Nanotechnology 10: 2062–2072.
Onafuye, H., Pieper, S., Mulac, D., Cinatl jr., J., Wass, M.N., Langer, K., and Michaelis, M. 2019. “Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance.” Beilstein Journal of Nanotechnology 10: 1707–1715.
Sun, J., Jung, D., Schoppa, T., Anderski, J., Picker, M.-T., Ren, Y., Mulac, D., Stein, N., Langer, K., and Kuckling, D. 2019. “Light-responsive serinol-based poylcarbonate and polyester as degradable scaffolds.” ACS Applied Bio Materials 2: 3038–3051.
Kimani, N.M., Backhaus, S., Matasyoh, J.C., Kaiser, M., Herrmann, F.C., Schmidt, T.J., and Langer, K. 2019. “Preparation of sesquiterpene lactone loaded - PLA nanoparticles and evaluation of their antitrypanosomal activity.” Molecules 24: 2110.
Partikel, K., Korte, R., Stein, N.C., Mulac, D., Herrmann, F.C., Humpf, H.-U., and Langer, K. 2019. “Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.” European journal of pharmaceutics and biopharmaceutics 2019: 70–80.
Mahlert, L., Anderski, J., Schoppa, T., Mulac, D., Sun, J., Kuckling, D., and Langer, K. 2019. “In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT.” International Journal of Pharmaceutics 565: 199–208.
Partikel, K., Korte, R., Mulac, D., Humpf, H.-U., and Langer, K. 2019. “Serum type and concentration both affecting the protein corona composition of PLGA nanoparticles.” Beilstein Journal of Nanotechnology 10: 1002–1015.
Mahlert, L., Anderski, J., Mulac, D., and Langer, K. 2019. “The impact of gastrointestinal mucus – new in vitro evaluation of promising mucus-penetrating PLGA-NP for photodynamic therapy in treatment of intestinal cancer.” European Journal of Pharmaceutical Sciences 133: 28–39.
Sun, J., Anderski, J., Picker, M.-T., Langer, K., and Kuckling, D. 2019. “Preparation of light-responsive aliphatic polycarbonate via versatile polycondensation for controlled degradation.” Macromolecular Chemistry and Physics 220: 1800539.
Anderski, J., Mahlert, L., Sun, J., Birnbaum, W., Mulac, D., Schreiber, S., Herrmann, F., Kuckling, D., and Langer, K. 2019. “Light-responsive nanoparticles based on new polycarbonates as innovative drug delivery systems for photosensitizers in PDT.” International Journal of Pharmaceutics 557: 182–191.

2018

Horster, L., Bernhardt, A., Kiehm, K., and Langer, K. 2018. “Conversion of PLGA nanoparticle suspensions into solid dosage forms via fluid bed granulation and tableting.” European journal of pharmaceutics and biopharmaceutics 134: 77–87.
Sun, J., Birnbaum, W., Anderski, J., Picker, M.-T., Mulac, D., Langer, K., and Kuckling, D. 2018. “Use of light-degradable aliphatic polycarbonate nanoparticles as drug carrier for photosensitizer.” Biomacromolecules 19: 4677–4690.
Anderski, J., Mahlert, L., Mulac, D., and Langer, K. 2018. “Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.” European journal of pharmaceutics and biopharmaceutics 129: 1–9.
Franz, J., Grünebaum, J., Schäfer, M., Mulac, D., Rehfeldt, F., Langer, K., Kramer, A., and Riethmüller, C. 2018. “Rhombic organization of microvilli domains found in a cell model of the human intestine.” PloS one 13 (1). doi: 10.1371/journal.pone.0189970.
Gossmann, R., Spek, S., Langer, K., and Mulac, D. 2018. “Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells.” Journal of Drug Delivery Science and Technology 43 (null): 430–438. doi: 10.1016/j.jddst.2017.11.002.
Raudszus, B., Mulac, D., and Langer, K. 2018. “A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells.” International Journal of Pharmaceutics 536 (1): 211–221. doi: 10.1016/j.ijpharm.2017.11.047.

2017

Mesken, J., Iltsche, A., Mulac, D., and Langer, K. 2017. “Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides −cellular uptake and enhanced gene delivery.” International Journal of Pharmaceutics 522: 198–209. doi: 10.1016/j.ijpharm.2017.03.006.
Lappe, S., Mulac, D., and Langer, K. 2017. “Polymeric nanoparticles – Influence of the glass transition temperature on drug release.” International Journal of Pharmaceutics 517: 338–347. doi: 10.1016/j.ijpharm.2016.12.025.

2016

John, C., Herz, T., Boos, J., Langer, K., and Hempel, G. 2016. “Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.” Talanta 146: 335–339. doi: 10.1016/j.talanta.2015.08.028.
Niehoff, A., Grünebaum, J., Moosmann, A., Mulac, D., Söbbing, J., Niehaus, R., Buchholz, R., Kröger, S., Wiehe, A., Wagner, S., Sperling, M., von Briesen, H., Langer, K., and Karst, U. 2016. “Quantitative bioimaging of platinum group elements in tumor spheroids.” Analytica Chimica Acta 938: 106–113. doi: 10.1016/j.aca.2016.07.021.
Lüdeker, D., Gossmann, R., Langer, K., and Brunklaus, G. 2016. “Crystal engineering of pharmaceutical co-crystals: "NMR crystallography" of niclosamide co-crystals.” Crystal Growth and Design 16 (6): 3087–3100. doi: 10.1021/acs.cgd.5b01619.
Gonnissen, D., Qu, Y., Langer, K., Öztürk, C., Zhao, Y., Chen, C., Seebohm, G., Düfer, M., Fuchs, H., Galla, H., and Riehemann, K. 2016. “Comparison of cellular effects of starch-coated SPIONs and poly(Lactic-co-glycolic acid) matrix nanoparticles on human monocytes.” International journal of nanomedicine 11 (null): 5221–5236. doi: 10.2147/IJN.S106540.

2015

Fahrländer, E., Schelhaas, S., Jacobs, A., and Langer, K. 2015. “PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterization and quantification of the PEGylation extent.” Nanotechnology 26 (14): 145103.. doi: 10.1088/0957-4484/26/14/145103.
John, C., Herz, T., Boos, J., Langer, K., and Hempel, G. 2015. “A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.” Talanta 146: 335–339.
Look, J., Wilhelm, N., von, Briesen H., Noske, N., Günther, C., Langer, K., and Gorjup, E. 2015. “Ligand-modified human serum albumin nanoparticles for targeted gene delivery.” Mol. Pharm. 12: 3202–3213.
Grünebaum, J., Söbbing, J., Mulac, D., and Langer, K. 2015. “Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.” International Journal of Pharmaceutics 496 (2): 942–952. doi: 10.1016/j.ijpharm.2015.10.023.
Afrimzon, E., Zurgil, N., Sobolev, M., Shafran, Y., Langer, K., Zlatev, I., Wronski, R., Windisch, M., von Briesen, H., Schmidt, R., Pietrzik, C., and Deutsch, M. 2015. “Detection and analysis of human serum albumin nanoparticles within phagocytic cells at the resolution of individual live cell or single 3D multicellular spheroid.” Journal of Nanoparticle Research 17 (12): 1–14. doi: 10.1007/s11051-015-3306-9.
Gossmann, R., Langer, K., and Mulac, D. 2015. “New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.” PloS one 10 (7). doi: 10.1371/journal.pone.0127532.
Spek, S., Häuser, M., Schäfer, M.M., and Langer, K. 2015. “Characterisation of PEGylated PLGA nanoparticles comparing the nanoparticle bulk to the particle surface using UV/Vis spectroscopy, SEC, 1H-NMR spectroscopy, and X-ray photoelectron spectroscopy.” Appl. Surf. Sci. 347.
Michaelis, M., Agha, B., Rothweiler, F., Löschmann, N., Voges, Y., Mittelbronn, M., Starzetz, T., Harter, P.N., Abhari, B.A., Fulda, S., Westermann, F., Riecken, K., Spek, S., Langer, K., Wiese, M., Dirks, W.G., Zehner, R., Cinatl, J., Wass, M.N., and Cinatl jr., J. 2015. “Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.” Scientific Reports 5.
Langer, K. 2015. “2nd Pharm School Symposium: Networked study in Münster.” Pharmazeutische Zeitung 160 (6).
Borgognoni, C., Mormann, M., Qu, Y., Schäfer, M., Langer, K., Öztürk, C., Wagner, S., Chen, C., Zhao, Y., Fuchs, H., and Riehemann, K. 2015. “Reaction of human macrophages on protein corona covered TiO2 nanoparticles.” Nanomedicine: Nanotechnology, Biology and Medicine 11 (2): 275–282. doi: 10.1016/j.nano.2014.10.001.
Gossmann, R., Fahrländer, E., Hummel, M., Mulac, D., Brockmeyer, J., and Langer, K. 2015. “Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.” European journal of pharmaceutics and biopharmaceutics 93: 80–87. doi: 10.1016/j.ejpb.2015.03.021.
Plöger, M., Sendker, J., Langer, K, and Schmidt, T.J. 2015. “Covalent modification of human serum albumin by the natural sesquiterpene lactone parthenolide.” Molecules 20: 6211–6223. doi: 10.3390/molecules20046211.

2014

Martínez Vera, N.P., Schmidt, R., Langer, K., Zlatev, I., Wronski, R., Auer, E., Havas, D., Windisch, M., von Briesen, H., Wagner, S., Stab, J., Deutsch, M., Pietrzik, C., Fazekas, F., and Ropele, S. 2014. “Tracking of magnetite labeled nanoparticles in the rat brain using MRI.” PloS one 9 (3): e92068.. doi: 10.1371/journal.pone.0092068.
John, C., and Langer, K. 2014. “Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes.” Journal of Chromatography A 1346: 97–106. doi: 10.1016/j.chroma.2014.04.048.
Niehoff, A.-C., Moosmann, A., Söbbing, J., Wiehe, A., Mulac, D., Wehe, C.A., Reifschneider, O., Blaske, F., Wagner, S., Sperling, M., von Briesen, H., Langer, K., and Karst, U. 2014. “A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.” Metallomics 6 (1): 77–81. doi: 10.1039/c3mt00223c.
Engel, A., Plöger, M., Mulac, D., and Langer, K. 2014. “Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.” International Journal of Pharmaceutics 461 (1): 137–144. doi: 10.1016/j.ijpharm.2013.11.044.
Langer, K. 2014. “Medicine-related problems in practice: Tablet splitting - (no) a problem? | Arzneimittelbezogene Probleme in der Praxis: Tablettenteilung - (k)ein Problem?” Pz Prisma 21 (2): 75–81.

2013

Meister, S., Zlatev, I., Stab, J., Docter, D., Baches, S., Stauber, R.H., Deutsch, M., Schmidt, R., Ropele, S., Windisch, M., Langer, K., Wagner, S., von Briesen, H., Weggen, S., and Pietrzik, C.U. 2013. “Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model.” Alzheimer's Research and Therapy 5 (6). doi: 10.1186/alzrt225.

2012

Storp, B., Engel, A., Böker, A., Plöger, M., and Langer, K. 2012. “Albumin nanoparticles with predictable size by desolvation procedure.” Journal of Microencapsulation 29 (2): 138–46. doi: 10.3109/02652048.2011.635218.

2011

Preuß, A., Chen, K., Hackbarth, S., Wacker, M., Langer, K., and Röder, B. 2011. “Photosensitizer loaded HSA nanoparticles II: In vitro investigations.” International Journal of Pharmaceutics 404 (1-2): 308–316. doi: 10.1016/j.ijpharm.2010.11.023.
Löw, K., Knobloch, T., Wagner, S., Wiehe, A., Engel, A., Langer, K., and von, Briesen H. 2011. “Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells.” Nanotechnology 22 (24): 245102.. doi: 10.1088/0957-4484/22/24/245102.
Löw, K., Wacker, M., Wagner, S., Langer, K., and von, Briesen H. 2011. “Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.” Nanomedicine: Nanotechnology, Biology and Medicine 7. doi: 10.1016/j.nano.2010.12.003.

2010

Chen, K., Wacker, M., Hackbarth, S., Ludwig, C., Langer, K., and Röder, B. 2010. “Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems.” Journal of Photochemistry and Photobiology B: Biology 101 (3): 340–7. doi: 10.1016/j.jphotobiol.2010.08.006.
Preuß, A., Hackbarth, S., Wacker, M., Knobloch, T., Langer, K., and Röder, B. 2010. “Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.” Journal of Controlled Release 148 (1): e117–e118.. doi: 10.1016/j.jconrel.2010.07.089.
Preuß, A., Chen, K., Hackbarth, S., Wacker, M., Langer, K., and Röder, B. 2010. “Photosensitizer loaded HSA nanoparticles II: In vitro investigations.” International Journal of Pharmaceutics 404: 308–316. doi: 10.1016/j.ijpharm.2010.11.023.
Wacker, M., Chen, K., Preuss, A., Possemeyer, K., Röder, B., and Langer, K. 2010. “Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.” International Journal of Pharmaceutics 393 (1-2): 253–62. doi: 10.1016/j.ijpharm.2010.04.022.
Wagner, S., Rothweiler, F., Anhorn, M.G., Sauer, D., Riemann, I., Weiss, E.C., Katsen-Globa, A., Michaelis, M., Cinatl, J., Schwartz, D., Kreuter, J., von, Briesen H., and Langer, K. 2010. “Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.” Biomaterials 31 (8): 2388–98. doi: 10.1016/j.biomaterials.2009.11.093.
Geiler, J., Michaelis, M., Naczk, P., Leutz, A., Langer, K., Doerr, H.W., and Cinatl, J. 2010. “N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.” Biochemical Pharmacology 79 (3): 413–420. doi: 10.1016/j.bcp.2009.08.025.

2009

Steinhauser, I., Langer, K., Strebhardt, K., and Spänkuch, B. 2009. “Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.” Journal of Drug Targeting 17 (8): 627–37. doi: 10.1080/10611860903118823.
Chen, K., Preuss, A., Hackbarth, S., Wacker, M., Langer, K., and Röder, B. 2009. “Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations.” Journal of Photochemistry and Photobiology B: Biology 96 (1): 66–74. doi: 10.1016/j.jphotobiol.2009.04.006.
Holzer, M., Vogel, V., Mäntele, W., Schwartz, D., Haase, W., and Langer, K. 2009. “Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage.” European journal of pharmaceutics and biopharmaceutics 72 (2): 428–37.
Müller, R.S., and Langer, K. 2009. “Nanotechnologie: Nanopartikel bringen Arzneistoffe sicher ans Ziel.” Pharmazeutische Zeitung 4.

2008

Anhorn, M.G., Wagner, S., Kreuter, J., Langer, K., and von, Briesen H. 2008. “Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles.” Bioconjugate Chemistry 19 (12): 2321–2331. doi: 10.1021/bc8002452.
Anhorn, M.G., Mahler, H.C., and Langer, K. 2008. “Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.” International Journal of Pharmaceutics 363 (1-2): 162–9. doi: 10.1016/j.ijpharm.2008.07.004.
Steinhauser, I.M., Langer, K., Strebhardt, K.M., and Spänkuch, B. 2008. “Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.” Biomaterials 29 (29): 4022–8. doi: 10.1016/j.biomaterials.2008.07.001.
Michaelis, M., Bliss, J., Arnold, S.C., Hinsch, N., Rothweiler, F., Deubzer, H.E., Witt, O., Langer, K., Doerr, H.W., Wels, W.S., and Cinatl, J. 2008. “Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins.” Clinical Cancer Research 14 (20): 6531–6537. doi: 10.1158/1078-0432.CCR-08-0821.
Spänkuch, B., Steinhauser, I., Wartlick, H., Kurunci-Csacsko, E., Strebhardt, K.I., and Langer, K. 2008. “Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.” Neoplasia 10 (3): 223–34. doi: 10.1593/neo.07916.
Langer, K., Anhorn, M.G., Steinhauser, I., Dreis, S., Celebi, D., Schrickel, N., Faust, S., and Vogel, V. 2008. “Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.” International Journal of Pharmaceutics 347 (1-2): 109–17. doi: 10.1016/j.ijpharm.2007.06.028.

2007

Dreis, S., Rothweiler, F., Michaelis, M., Cinatl, J., Kreuter, J., and Langer, K. 2007. “Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.” International Journal of Pharmaceutics 341 (1-2): 207–14. doi: 10.1016/j.ijpharm.2007.03.036.
Pereverzeva, E., Treschalin, I., Bodyagin, D., Maksimenko, O., Langer, K., Dreis, S., Asmussen, B., Kreuter, J., and Gelperina, S. 2007. “Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.” International Journal of Pharmaceutics 337 (1-2): 346–56. doi: 10.1016/j.ijpharm.2007.01.031.
Kreuter, J., Hekmatara, T., Dreis, S., Vogel, T., Gelperina, S., and Langer, K. 2007. “Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.” Journal of Controlled Release 118 (1): 54–8. doi: 10.1016/j.jconrel.2006.12.012.

2006

Steinhauser, I., Spänkuch, B., Strebhardt, K., and Langer, K. 2006. “Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.” Biomaterials 27 (28): 4975–83. doi: 10.1016/j.biomaterials.2006.05.016.
Michaelis, K., Hoffmann, M.M., Dreis, S., Herbert, E., Alyautdin, R.N., Michaelis, M., Kreuter, J., and Langer, K. 2006. “Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.” Journal of Pharmacology and Experimental Therapeutics 317 (3): 1246–53. doi: 10.1124/jpet.105.097139.

2005

Dinauer, N., Balthasar, S., Weber, C., Kreuter, J., Langer, K., and von, Briesen H. 2005. “Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.” Biomaterials 26 (29): 5898–906. doi: 10.1016/j.biomaterials.2005.02.038.
Balthasar, S., Michaelis, K., Dinauer, N., von, Briesen H., Kreuter, J., and Langer, K. 2005. “Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes.” Biomaterials 26 (15): 2723–32. doi: 10.1016/j.biomaterials.2004.07.047.

2004

Wartlick, H., Michaelis, K., Balthasar, S., Strebhardt, K., Kreuter, J., and Langer, K. 2004. “Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.” Journal of Drug Targeting 12 (7): 461–71. doi: 10.1080/10611860400010697.
Michaelis, M., Langer, K., Arnold, S., Doerr, H.W., Kreuter, J., and Cinatl, J. 2004. “Pharmacological activity of DTPA linked to protein-based drug carrier systems.” Biochemical and Biophysical Research Communications 323 (4): 1236–40. doi: 10.1016/j.bbrc.2004.08.223.
Brzoska, M., Langer, K., Coester, C., Loitsch, S., Wagner, T.O., and Mallinckrodt, C. 2004. “Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.” Biochemical and Biophysical Research Communications 318 (2): 562–70. doi: 10.1016/j.bbrc.2004.04.067.
Brzoska, M., Langer, K., Coester, C., Loitsch, S., Wagner, T.O.F., and Mallinckrodt, C.V. 2004. “Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.” Biochemical and Biophysical Research Communications 318 (2): 562–570. doi: 10.1016/j.bbrc.2004.04.067.
Wartlick, H., Spänkuch-Schmitt, B., Strebhardt, K., Kreuter, J., and Langer, K. 2004. “Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.” Journal of Controlled Release 96 (3): 483–95. doi: 10.1016/j.jconrel.2004.01.029.
Wartlick, H., Spänkuch-Schmitt, B., Strebhardt, K., Kreuter, J., and Langer, K. 2004. “Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles.” Journal of Controlled Release 96 (3): 483–495. doi: 10.1016/j.jconrel.2004.01.029.

2003

Rhaese, S., von, Briesen H., Rübsamen-Waigmann, H., Kreuter, J., and Langer, K. 2003. “Human serum albumin-polyethylenimine nanoparticles for gene delivery.” Journal of Controlled Release 92 (1-2): 199–208.
Langer, K.Balthasar S., Vogel, V.Dinauer N., and von Briesen H., Schubert D. 2003. “Optimization of the preparation process for human serum albumin (HSA) nanoparticles.” International Journal of Pharmaceutics 257 (1-2): 169–80. doi: 10.1016/S0378-5173(03)00134-0.

2002

Michaelis, M., Langer, K., Vogel, J.U., Kreuter, J., Rabenau, H., Doerr, H.W., and Cinatl, J. 2002. “In vitro antiviral activity of aphidicolin and its derivates - Synergistic effects of aphidicolin with other antiviral drugs.” Arzneimittel-Forschung 52 (5): 393–399.
Michaelis, M., Cinatl, J., Cinatl, J., Pouckova, P., Langer, K., Kreuter, J., and Matousek, J. 2002. “Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice.” Anti-Cancer Drugs 13 (2): 149–154. doi: 10.1097/00001813-200202000-00006.

2000

Weber, C., Reiss, S., and Langer, K. 2000. “Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups.” International Journal of Pharmaceutics 211 (1-2): 67–78. doi: 10.1016/S0378-5173(00)00590-1.
Michaelis, M., Vogel, J.U., Cinati, J., Langer, K., Kreuter, J., Schwabe, D., Driever, P.H., and Cinati, J. 2000. “Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine.” Anti-Cancer Drugs 11 (6): 479–485. doi: 10.1097/00001813-200007000-00009.
Michaelis, M., Matousek, J., Vogel, J.U., Slavik, T., Langer, K., Cinatl, J., Kreuter, J., Schwabe, D., and Cinatl, J. 2000. “Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro.” Anti-Cancer Drugs 11 (5): 369–76. doi: 10.1097/00001813-200006000-00007.
Langer, K., Coester, C., Weber, C., von, Briesen H., and Kreuter, J. 2000. “Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid.” European journal of pharmaceutics and biopharmaceutics 49 (3): 303–7.
Coester, C.J., Langer, K., von, Briesen H., and Kreuter, J. 2000. “Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake.” Journal of Microencapsulation 17 (2): 187–93. doi: 10.1080/026520400288427.
Coester, C.J., Langer, K., von, Briesen H., and Kreuter, J. 2000. “Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake.” Journal of Microencapsulation 17 (2): 187–193.
Weber, C., Kreuter, J., and Langer, K. 2000. “Desolvation process and surface characteristics of HSA-nanoparticles.” International Journal of Pharmaceutics 196 (2): 197–200. doi: 10.1016/S0378-5173(99)00420-2.
Coester, C., Kreuter, J., von, Briesen H., and Langer, K. 2000. “Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA).” International Journal of Pharmaceutics 196 (2): 147–9. doi: 10.1016/S0378-5173(99)00409-3.
Weber, C., Coester, C., Kreuter, J., and Langer, K. 2000. “Desolvation process and surface characterisation of protein nanoparticles.” International Journal of Pharmaceutics 194 (1): 91–102. doi: 10.1016/S0378-5173(99)00370-1.

1999

Weber, C., Michaelis, M., Vogel, J.U., Cinatl, J., Kreuter, J., and Langer, K. 1999. “Simple and efficient method for the detection of diethylenetriaminepentaacetic acid.” Journal of Chromatography B 736 (1-2): 299–303. doi: 10.1016/S0378-4347(99)00456-9.

1998

Aliautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kreuter, J., and Kharkevich, D.A. 1998. “The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles | Dostavka loperamida v mozg s pomoshch'iu polibutiltsianoarilatnykh nanochastits.” Eksperimental'naia i klinicheskaia farmakologiia 61 (1): 17–20.
Aliautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kreuter, J., and Kharkevich, D.A. 1998. “[The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].” Eksperimental'naia i klinicheskaia farmakologiia 61 (1): 17–20.

1997

Langer, K., Zimmer, A., and Kreuter, J. 1997. “Acrylic nanoparticles for ocular drug delivery.” S.T.P. Pharma Sciences 7 (6): 445–451.
Langer, K., Stieneker, F., Lambrecht, G., Mutschler, E., and Kreuter, J. 1997. “Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part II: Arecaidine propargyl ester and pilocarpine loading and in vitro release.” International Journal of Pharmaceutics 158 (2): 211–217. doi: 10.1016/S0378-5173(97)00256-1.
Langer, K., Mutschler, E., Lambrecht, G., Mayer, D., Troschau, G., Stieneker, F., and Kreuter, J. 1997. “Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part III: Evaluation as drug delivery system for ophthalmic applications.” International Journal of Pharmaceutics 158 (2): 219–231. doi: 10.1016/S0378-5173(97)00255-X.
Langer, K., Lambrecht, G., Moser, U., Mutschler, E., and Kreuter, J. 1997. “Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester.” Journal of Chromatography B: Biomedical applications 692 (2): 345–350. doi: 10.1016/S0378-4347(96)00521-X.
Alyautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kharkevich, D.A., and Kreuter, J. 1997. “Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.” Pharmaceutical Research 14 (3): 325–8. doi: 10.1023/A:1012098005098.

1996

Pirker, S., Kruse, J., Noe, C., Langer, K., Zimmer, A., and Kreuter, J. 1996. “Characterization of polybutyleyanoacrylate nanoparticles. Part II: Determination of polymer content by NMR-analysis.” International Journal of Pharmaceutics 128 (1-2): 189–195. doi: 10.1016/0378-5173(95)04305-5.
Langer, K., Marburger, C., Berthold, A., Kreuter, J., and Stieneker, F. 1996. “Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part I: Preparation and physicochemical characterization.” International Journal of Pharmaceutics 137 (1): 67–74. doi: 10.1016/0378-5173(96)89589-5.

1994

Langer, K., Seegmüller, E., Zimmer, A., and Kreuter, J. 1994. “Characterisation of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans.” International Journal of Pharmaceutics 110 (1): 21–27. doi: 10.1016/0378-5173(94)90371-9.

Research Article (Book Contributions)

2015

Langer, K. 2015. “Überblick über Messmethoden und deren physikalische Hintergründe: Submikron.” in Partikel in der Pharmaproduktion, edited by F. Stieneker.

2005

Langer, K. 2005. “Peptide nanoparticles.” in Nanotechnologies for the Life Sciences, Vol. 2: Biological and Pharmaceutical Nanomaterials, edited by C. Kumar.

Supervised Doctoral Studies

Kotschate, Olivia: Herstellung proteinbasierter Nanopartikel mittels Mikrofluidik
Further Supervisor
Steiner, Denise
Reviewers
Langer, Klaus
Steiner, Denise
Kurze, Tobias Maximilian (2026): Zellspezifisches Targeting durch Oberflächenmodifizierung proteinbasierter Nanokapseln.
Supervisors
Ferenz, K.
Reviewers
Langer, K.
Ferenz, K.
Horky, Corinna (2026): Entwicklung und zellbiologische Bewertung Stimulus-responsiver Nanopartikel zur Anwendung in der Tumortherapie
Reviewers
Langer, Klaus
Kuckling, Dirk
Paul, Kris (2025): Entwicklung einer Enzymsubstitutionstherapie bei Transglutaminase 1-defizienter lamellärer Ichthyose
Further Supervisor
Hempel, Georg
Reviewers
Langer, Klaus
Hempel, Georg
Begasse, Theresa (2025): Nanopartikuläre Arzneiformen zum Einsatz bei der Therapie vaskulärer Erkrankungen
Reviewers
Langer, Klaus
Rutsch, Frank
Kramer, Maurice (2025): Entwicklung von Redox- und pH-sensitiven Nanopartikel-Systemen.
Supervisors
Kuckling, Dirk
Reviewers
Langer, Klaus
Kuckling, Dirk
Bodes, Jacqueline (2025): Protein delivery in skin: In vitro analysis of a novel therapeutic approach in Netherton Syndrome.
Further Supervisor
Liebau, Eva
Reviewers
Langer, Klaus
Liebau, Eva
Laabs, Moritz (2025): Lipoprotein-imitierende, nanopartikuläre Arzneistoffträgersysteme zur Überwindung der Blut-Hirn-Schranke
Further Supervisor
Humpf, Hans-Ulrich
Reviewers
Langer, Klaus
Steiner, Denise
Lins, Anika (2025): Untersuchungen zur Proteincorona an kolloidalen Arzneistoffträgern.
Further Supervisor
Humpf, Hans-Ulrich
Reviewers
Langer, Klaus
Humpf, Hans-Ulrich
Tran, Xenia (2025): Antikörper-modifizierte Nanopartikel zum spezifischen Targeting von Tumoren.
Further Supervisor
Düfer, Martina
Reviewers
Langer, Klaus
Düfer, Martina
Hortmann, Pascal (2024): Untersuchungen zur Formulierung flüssiger Arzneistoffe in festen Arzneiformen
Reviewers
Langer, Klaus
Lehr, Matthias
Adick, Annika (2023): HSA-stabilisierte Nanopartikel für intravenöse Anwendungen.
Further Supervisor
Lehr, Matthias
Reviewers
Langer, Klaus
Lehr, Matthias
Hester, Sarah (2023): Entwicklung proteinbasierter Nanokapseln als Trägersystem für Arzneistoffe
Reviewers
Langer, Klaus
Ferenz, Katja
Weitzel, Johanna (2023): Patientenrelevanz generischer Substitution am Beispiel von Levodopa
Reviewers
Langer, Klaus
Hempel, Georg
Prell, Katharina (2023): Entwicklung und zellbiologische Testung von Nanopartikeln zur Überwindung der Blut-Hirn-Schranke.
Further Supervisor
Wünsch, Bernhard
Reviewers
Langer, Klaus
Wünsch, Bernhard
Spreen, Hendrik (2022): Untersuchungen zur Ausbildung einer Proteincorona an kolloidalen Arzneistoffträgern.
Reviewers
Langer, Klaus
Humpf, Hans-Ulrich
Linß, Franziska Kerstin (2022): Nanopartikuläre Arzneiformen zum Einsatz bei der Therapie vaskulärer Erkrankungen.
Further Supervisor
Rutsch, Frank
Reviewers
Langer, Klaus
Rutsch, Frank
Schoppa, Timo (2022): Entwicklung Stimuli-responsiver nanopartikulärer Arzneistoffträgersysteme
Reviewers
Langer, Klaus
Kuckling, Dirk
Barth, Christina (2021): Zellspezifisches Targeting proteinbasierter Nanopartikel
Further Supervisor
Düfer, Martina
Neufeld, Nelly (2020): Nanopartikuläre DNA-Trägersysteme als alternative nicht-virale Gen-Vektoren
Further Supervisor
Jose, Joachim
Stein, Nora (2020): Proteinstabilisierung nanopartikulärer Arzneiformen
Further Supervisor
Jose, Joachim
Sahnen, Frederic (2020): Überführung von Arzneistoff-Nanosuspensionen zu festen Arzneiformen.
Further Supervisor
Lehr, Matthias
Backhaus, Solveig Johanna (2020): Oberflächenmodifizierte PLGA-Nanopartikel zur Überwindung der Blut-Hirn-Schranke.
Further Supervisor
Wünsch, Bernhard
Wünsch, Angelika (2020): Imitation von Lipoproteinen als nanopartikuläre Arzneistoffträgersysteme
Further Supervisor
Humpf, Hans-Ulrich
Alberding, Gerrit (2020): Nanopartikuläre Arzneiformen zur Überwindung der gastrointestinalen Barriere.
Further Supervisor
Lehr, Matthias
Frank, Katharina (2020): Mukoadhäsive Darreichungsformen zur nanopartikulären photodynamischen Tumortherapie
Further Supervisor
Hensel, Andreas
Grothe, Stephanie (2019): Physikochemische Charakterisierung von Nanopartikeln auf Basis ausgewählter Eudragit®-Polymere
Keuth, Jacqueline (2019): Nanopartikuläre Arzneiformen zum Einsatz in der Therapie arterieller Calcifizierungen
Motealleh, Andisheh (2019): Synthesis of nanocomposite hydrogels and stereoselective cell-material interactions.
Partikel, Katrin (2019): Untersuchung der Proteinadsorption an PLGA-Nanopartikeln.
Pieper, Sebastian (2019): Entwicklung und Charakterisierung von Nanopartikeln zur Resistenzüberwindung von Tumorzellen
Mahlert, Laura (2019): Zellbiologische Bewertung Licht-responsiver Nanosysteme zur Anwendung in der intestinalen Tumortherapie.
Anderski, Juliane (2019): Entwicklung Licht-responsiver Nanopartikel als Arzneistoffvehikel für die photodynamische Tumortherapie.
Kimani, Mark Njogu (2019): Antiprotozoal Agents from Plants of the Family Asteraceae, Structure-Activity-Relationships and Formulation of Selected Compounds into PLA Nanoparticles
Further Supervisor
Schmidt, Thomas
Reviewer
Schmidt, Thomas J. Langer, Klaus
Esch, Stefan (2018): Intracellular signaling pathways involved in human keratinocyte differentiation induced by natural products
Further Supervisor
Hensel, Andreas
Reviewers
Hensel, Andreas
Langer, Klaus
Mesken, Julia (2017): Oberflächenmodifizierte HSA-Nanopartikel als nicht-virale DNA-Vektoren.
Raudszus, Bastian (2017): Entwicklung und biologische Testung oberflächenmodifizierter PLA-Nanopartikel zur Überwindung der Blut-Hirn-Schranke
Eidam, Sebastian (2017): Stakeholdermanagement bei der kooperativen Entwicklung von Arzneimitteln
Further Supervisor
Leker, Jens
Wessels, Lisa (2017): Nanokapseln - Herstellungsmethoden, Charakterisierung und in vitro-Untersuchungen
Further Supervisor
Wünsch, Bernhard
Horster, Lutz (2017): Wirbelschichtgranulierung mit polymeren Nanopartikeln
Thoma, Frédérique Nicola (2017): Entwicklung und Charakterisierung kolloidaler Trägersysteme für Proteine
Grünebaum, Jonas (2016): In vitro Charakterisierung von nanopartikulären Trägersystemen für die photodynamische Therapie
Further Supervisor
Schwerdtle, Tanja
Gossmann, Rebecca (2016): Entwicklung kationischer Nanopartikel und deren Zellinteraktion
Fröhleke, Anna Katharina (2016): Möglichkeiten und Grenzen von PK-Sim® in der pädiatrischen Onkologie am Beispiel der Anthrazykline
Further Supervisors
Hempel, Georg
Boos, Joachim
Lappe, Svenja Carina (2016): Glasübergangstemperatur und Freisetzungsverhalten polymerer Nanopartikel
Spek, Silvia (2015): Entwicklung und Charakterisierung nanopartikulärer Systeme zur Analyse von Partikel-Zell-Interaktionen
Look, Jennifer (2015): Neuartige Liganden-modifizierte Nanopartikel als Trägersysteme für Nukleinsäuren
Further Supervisor
Jose, Joachim
Fahrländer, Eva-Maria (2014): Entwicklung und Charakterisierung PEGylierter HSA-Nanopartikel
Zlatev, Iavor (2014): Entwicklung von Nanopartikeln als Träger für Alzheimer Therapeutika
Further Supervisor
Karst, Uwe
John, Cornelia (2014): Asymmetrische Fluss-Feldfluss-Fraktionierung zur Charakterisierung kolloidaler Systeme
Further Supervisor
Schönhoff, Monika
Hindel, Stefan (2014): Entwicklung einer nanopartikulären Arzneimittelformulierung auf der Basis von PLGA zum aktiven Drug-Targeting von Doxorubicin an Tumorzellen mittels des monoklonalen Antikörpers DI17E6
Further Supervisor
Hensel, Andreas
Häuser, Manuel (2014): Entwicklung pH-schaltbarer Nanopartikelsysteme zur intrazellulären Wirkstofffreisetzung
Further Supervisor
Schönhoff, Monika
Dickschen, Kristin Josefine Ruth (2014): Überwindung der CYP2D6 vermittelten Tamoxifenresistenz bei postmenopausalen Brustkrebs: ein PBPK-Ansatz
Further Supervisor
Hempel, Georg
von Storp, Bernhard (2013): Entwicklung nanopartikulärer Arzneiformen für niedermolekulare Kinase-Inhibitoren zur Anwendung in der Tumortherapie
Further Supervisor
Verspohl, Eugen
Engel, Andrea (2013): Nanopartikuläre Trägersysteme für Tetrapyrrole
Further Supervisor
Schönhoff, Monika
Plöger, Michael (2013): Development of nanoparticular Drug Formulations for biologically active secondary Plant Constituents (Thesis written in German)
Further Supervisor
Schmidt, Thomas
Reviewer
Langer, Prof. Dr. Klaus Schmidt, Thomas J., Prof. Dr.
Böker, Anne (2013): Partikuläre Arzneiformen zur kontrollierten Proteinfreisetzung
Klassert, Denise (2012): Angiogenes Potential chemoresistenter und persistenter HCMV-infizierter Neuroblastomzellen
Holzer, Melisande (2010): Antikörperbeladene PLGA-Nanopartikel als Trägersystem für eine verzögerte Wirkstofffreisetzung in der Tumortherapie
Geiler, Janina (2010): Untersuchungen der Immunreaktion in Influenza-A-infizierten Zellen und Analyse von potentiellen antiviralen Substanzen
Wacker, Matthias (2010): Entwicklung zellspezifischer Arzneistoffträger zur Tumortherapie

Scientific Talks

Anderski, Juliane; Mahlert, Laura 2017: “Interactions of nanoparticles with mucus - the first barrier before reaching intestinal cells”. Bad Herrenalber Transporter- und Barrieretage, Bad Herrenalb, Deutschland, May 16, 2017.
Raudszus, Bastian; Mulac, Dennis; Langer, Klaus 2016: “Apo E-modification of PLA-nanoparticles enhances cellular uptake into brain endothelium”. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, Vereinigtes Königreich, Apr 6, 2016.

Honors

10.2016: PHOENIX Pharmazie Wissenschaftspreis – PHOENIX group

01.2016: Lehrpreis – Universität Münster

06.2008: Preis des Fachbereichs Biochemie, Chemie und Pharmazie für exzellente Lehre – Goethe-Universität, Frankfurt

01.2003: Adolf Messer Stiftungspreis – Adolf Messer Stiftung
Teaching

Lecture:

"Pharmazeutische Technologie einschließlich Medizinprodukte" (5th, 6th and 7th semester)

"Biopharmazie einschl. arzneiformenbezogener Pharmakokinetik" (5th, 6th and 7th semester)

Staff

Dissertations, MSc

Dissertation

Max Hesse

Pharmacist

Room: C.110.181
Phone: +49 (0)251 - 83-39897
E-Mail:mhesse1(AT)uni-muenster(DOT)de

Dissertation

Finn Kortenbusch

Pharmacist

Room: C.110.181
Phone: +49 (0)251 - 8339883
E-Mail: f.kortenbusch(AT)uni-muenster(DOT)de

Dissertation

Olivia Kotschate

Pharmacist

Room: C.110.182
Phone: +49 (0)251 - 83-39885
E-Mail: olivia(DOT)kotschate(AT)uni-muenster(DOT)de

Dissertation

Tobias Kurze

Pharmacist

Room C.110.182
Phone: +49 (0)251 - 83-39885
E-Mail: tobias.kurze(AT)uni-muenster(DOT)de

Dissertation

Simon Pohl

MSc Molecular Biotechnology

Room C.110.181
Phone: +49 (0)251 - 83-39897
E-Mail: simon.pohl(AT)uni-muenster(DOT)de

MSc

Prof. Langer: Research and teaching

Academic Education

Positions

Honors

Research Articles (Journals)

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2000

1999

1998

1997

1996

1994

Research Article (Book Contributions)

2015

2005

Honors

Teaching

Lecture:

Staff

Dissertations, MSc